RenaSci Enters Strategic Alliance with Sygnature Discovery 16/02/2016 02:15

RenaSci has entered into a strategic alliance with Sygnature Discovery in the therapeutic areas of metabolic and CNS disorders. This exciting new collaboration will cement the existing close, working relationship between Sygnature and RenaSci, accelerating clients’ projects in metabolic and CNS disorders from discovery into development.

Sygnature is the UK’s largest, independent provider of drug discovery services for the global pharmaceutical and biotechnology industry with over 110 experienced scientists located in modern, purpose-built laboratories at BioCity, Nottingham. Sygnature’s capabilities, which include medicinal chemistry, computational chemistry, bioscience (in vitro), DMPK and physical sciences and protein crystallography, will be complemented by our in vivo animal models and assays for evaluating the efficacy, mode of action and side-effect profiles of new drugs to treat diabetes, obesity and CNS disorders.

We believe that our clients will benefit from this alliance by having access to a wide range of fully-integrated drug discovery services, at the same location, from two leading service providers with international reputations for delivering drug candidates into the clinic. The close proximity of the two companies at the BioCity site, coupled with our effective working relationship, will allow novel compounds designed, synthesised and tested in vitro at Sygnature, to rapidly progress to in vivo testing in appropriate animal models in our laboratories.

To see the full press release please click here.

RenaSci will continue to provide pre-clinical services and consultancy independently.